Webcast From The 4th Annual West Cancer Center Oncology Conference® - priME Oncology
Webcast
Webcast

Webcast From The 4th Annual West Cancer Center Oncology Conference®

Not a member of My prIME? Join now for instant access.

An update on practice-changing data on women’s cancers, genitourinary malignancies, hematologic malignancies, emerging issues in oncology, surgical oncology coordination, lung cancer, and a case-based discussion of the WCC molecular tumor board.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 19, 2018

Expiration Date

Dec 19, 2019

Immunotherapy in gynecologic malignancies? Are we there yet?
Rebecca Arend, MD

HER2-positive breast cancer: Beyond the plateau
Sunil Verma, MD, MSEd, FRCPC

CDK 4/6 inhibitors: How to choose and where do we go from here?
Angela DeMichele, MD, MSCE

Immunotherapy and targeted therapy for advanced kidney cancer: Are combinations ready for primetime?
W. Kimryn Rathmell, MD, PhD

Immunotherapy and targeted therapy for advanced bladder cancer
Derek Raghavan MD, PhD, FACP, FRACP, FASCO, FAAAS

The evolving role of germline mutation testing in GU cancers: Who, when, and how to test
Brian Shuch, MD

Clifton G. Hollis Memorial Lecture
A case of me: Clinical cancer sequencing – The future of precision medicine
Lukas D. Wartman, MD

Chimeric antigen receptor (CAR) and adoptive cell transfer: Review of the data and a roadmap to implementation in a community setting
Frederick Locke, MD

AML in the Eldery
John S. Welch, MD, PhD

DLBCL: Double-hit, triple-hit, and how to manage them
Amanda Cashen, MD

Multiple myeloma: Updates on new and novel strategies
Shaji Kumar, MD

Geriatric oncology: The key is geriatric assessment
Hyman B. Muss, MD

Palliative care: How to make the best of the worst
Eric Roeland, MD

Emerging molecular biomarkers for IO: Looking beyond PD-1/PD-L1
Melissa Johnson, MD

Intrahepatic cholangiocarcinoma: Surgical and nonsurgical liver directed therapy
Paxton V. Dickson, MD, FACS

Extrahepatic bile duct cancers: Addressing the challenges of diagnosis, surgical therapy, and palliation
Mark J. Truty, MD, MSc, FACS

Perspective on systemic therapies and molecular profiling for biliary tract cancers
Milind Javle, MD

Resectable pancreatic cancer: What is the appropriate sequencing of therapy?
Syed A. Ahmad, MD, FACS

Further updates on molecularly driven treatment of lung cancer
Daniel B. Costa, MD, PhD, MMSc

  • Syed A. Ahmad, MD, FACSUniversity of Cincinnati Cancer Institute
    Cincinnati, Ohio, United States
  • Rebecca Arend, MDUniversity of Alabama at Birmingham
    Comprehensive Cancer Center
    Birmingham, Alabama, United States
  • Amanda Cashen, MDWashington University School of Medicine
    St Louis, Missouri, United States
  • Daniel B. Costa, MD, PhD, MMSc Dana-Farber Havard Cancer Center
    Boston, Massachusetts, United States
  • Angela DeMichele, MD, MSCEPerelman Center for Advanced Medicine
    Philadelphia, Pennsylvania, United States
  • Paxton V. Dickson, MD, FACSWest Cancer Center
    University of Tennessee Health Science Center
    Memphis, Tennessee, United States
  • Milind Javle, MDThe University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • Melissa Johnson, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Shaji Kumar, MDMayo Clinic
    Rochester, Minnesota, United States
  • Frederick Locke, MDMoffitt Cancer Center
    Tampa, Florida, United States
  • Hyman B. Muss, MDUniversity of North Carolina
    Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina, United States
  • W. Kimryn Rathmell, MD, PhDVanderbilt University
    Nashville, Tennessee, United States
  • Derek Raghavan MD, PhD, FACP, FRACP, FASCO, FAAASLevine Cancer Institute
    Charlotte, North Carolina, United States
  • Eric J. Roeland, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Brian Shuch, MDYale School of Medicine
    New Haven, Connecticut, United States
  • Mark J. Truty, MD, MSc, FACSMayo Clinic
    Rochester, Minnesota, United States
  • Sunil Verma, MD, MSEd, FRCPCTom Baker Cancer Centre
    Calgary, Alberta, Canada
  • Lukas D. Wartman, MDThe Clifton G. Hollis Memorial Visiting Professor
    Washington University Medical School
    St Louis, Missouri, United States
  • John S. Welch, MD, PhDWashington University Medical School
    St Louis, Missouri, United States

This educational activity is specifically designed to meet the needs of practicing medical oncologists, hematologists, surgeons, radiation oncologists, pathologists, nurses, and other healthcare professionals involved in the treatment of cancer.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Evaluate recent clinical data on the novel targeted and immunologic approaches for breast and ovarian cancers
  • Incorporate new diagnostic strategies and immunotherapy and targeted therapies into the treatment algorithms for genitourinary malignancies, including kidney, bladder, and prostate cancers
  • Discuss new and emerging treatment options for hematologic malignancies
  • Evaluate the role of surgery, radiation therapy, and systemic therapies for the treatment of pancreatic and bile duct cancers
  • Formulate strategies to integrate new and emerging targeted strategies and immunotherapy into standard treatment for lung cancer

Nurses

  • Identify the role of nurses in managing the practical challenges in providing optimal supportive care for cancer, including palliative care, pain management, and immune-related adverse event management

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Clovis Oncology; and Novartis Oncology.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ahmad has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Arend has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cashen has disclosed membership on an advisory committee or review panel from Astellas and Versatem. She also disclosed speaking and teaching for Celgene and Seattle Genetics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Costa has disclosed that he has received consulting fees from AstraZeneca, Pfizer, and Takeda. He also disclosed independent contracting for Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr DeMichele has disclosed as an independent contractor for Calithera, Genentech, Novartis, and Pfizer. She also disclosed speaking and teaching for Pfizer at Asian Clinical Oncology Society. Her spouse disclosed participation on a data safety monitoring board for Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Dickson has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Javle has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Johnson has disclosed institutional research funds (no personal funds) to her institution for AbbVie; Adaptimmune; Amgen; Apexigen; Array BioPharma; AstraZeneca; BeiGene; BerGenBio; Birdie; Boehringer Ingelheim; Checkpoint Therapeutics; Corvus; Cytomx; Daiichi Sankyo; Dynavax; EMD Serono; G1 Therapeutics; Genentech/Roche; Genmab; Genocea; Gritstone; Hengrui Therapeutics, INC; Incyte; Janssen; Lilly; LOXO; Lycera; Merck; Mirati Therapeutics; Neovia; Novartis; Pfizer; Regeneron; Sanofi; Stemcentrix; Syndax; and Tarveda. She also disclosed that she received consulting fees for her institution from AstraZeneca, Boehringer Ingelheim, Calithera, Celgene, Genentech/Roche, LOXO, Merck, Mirati, and Sanofi. She disclosed that her spouse has received fees as a contract lobbyist from Astellas and Otsuka Pharmaceuticals. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kumar has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, KITE, Merck, Oncopeptides, Reddy’s Lab, and Takeda. He also disclosed independent contracting for AbbVie; Amgen; Bristol-Myers Squibb; Celgene; KITE; Medimmune; Merck & Co. Inc; Roche; and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Locke has disclosed that he has received consulting fees from Cellular Biomedicine Group, Inc. He also disclosed membership on advisory committees or review panels for Kite Pharma and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Muss has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Raghavan has disclosed receipt of a grant for lung cancer screening from the Bristol-Myers Squibb Foundation. He also disclosed unpaid membership on the Caris Life Sciences Medical Advisory Board.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rathmell has disclosed that her spouse has received grant or research support from Calithera, Incyte, Kadmon, and Tempest. She also disclosed her spouse has received consulting fees from Caribou, Calithera, Immunext, Johnson & Johnson, Pfizer, and Roche. She further disclosed her spouse is a founder with stock ownership with Caribou and Sitryx. She disclosed her spouse has membership on an advisory board for Caribou, Itessa, and . She also disclosed institutional research support from AstraZeneca, Calithera, Novartis, Peloton, Pfizer, Roche, and Tracon. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Roeland has disclosed that he has received consulting fees from Asahi, BASF American Imaging, Helsinn, and Heron Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shuch has disclosed that he has received consulting fees from Peloton Therapeutics and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Truty has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Verma has disclosed membership on advisory committees or review panels for Amgen, AstraZeneca, Daichi Sankyo, Lilly, Novartis, Pfizer, Roche, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wartman has disclosed that he has received consulting fees from Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Welch has disclosed that he has received consulting fees from Rigel Pharmaceuticals. He also disclosed honoraria for promotional speaker’s bureau and research support from Janssen Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.